Key points
- Approval of Nasodine Nasal Spray in Indonesia
- Successful manufacturing and filing for approval in the Philippines
- Launch of Nasodine Throat Spray in Singapore
- Major growth in US sales of Nasodine Nasal Spray
- New patents granted in Europe, Australia, Canada, New Zealand, and the Philippines
Full summary
Firebrick Pharma Ltd reported positive achievements in the 2026 financial year, including the approval of Nasodine Nasal Spray in Indonesia, the largest market in Southeast Asia, and successful completion of manufacturing and filing for approval in the Philippines. The company also launched Nasodine Throat Spray in Singapore, its first line extension under the Nasodine brand, and experienced major growth in US sales of Nasodine Nasal Spray. Additionally, new patents were granted in Europe, Australia, Canada, New Zealand, and the Philippines. The company expects to achieve further goals in the coming financial year, including the launch in Indonesia, marketing approval in the Philippines, and the launch of a third innovative Nasodine product. With the recent appointments of Rick Legleiter and Al Moghaddam as Non-executive Directors, and Nilesh Wadhwa as Head of Business Development & Licensing, the company has bolstered its commercial competencies. The fundamentals and prospects of the company remain strong, with a product that the world needs and a portfolio of new products coming through under the Nasodine brand.
Guidance
Revenues from ordinary activities: 106,293 (decrease of 63.82%)
Outlook
The company expects to achieve further goals in the coming financial year, including the launch in Indonesia, marketing approval in the Philippines, and the launch of a third innovative Nasodine product.